Veru

VERUPhase 3

Veru Inc. is a biopharmaceutical company targeting significant unmet needs in cardiometabolic and inflammatory diseases with its two lead clinical candidates. The company is strategically positioning enobosarm as a combination therapy to address the muscle-wasting side effect of popular GLP-1 receptor agonists for weight loss, aiming to improve the quality of weight reduction. Concurrently, it is developing sabizabulin to target the inflammatory drivers of atherosclerosis. Veru operates as a public company and is led by a management team with extensive experience in drug development and commercialization.

Market Cap

$72.3M

Pipeline

4 in Phase 3

Patents

—

Publications

—

AI Company Overview

Cardiometabolic DiseasesInflammatory DiseasesObesityAtherosclerosis

Technology Platform

The company is advancing two distinct small molecule platforms: Selective Androgen Receptor Modulators (SARMs) for muscle preservation and oral microtubule disruptors for broad anti-inflammatory effects.

Pipeline

12 drugs in pipeline4 in Phase 3

Drug	Indication	Stage
VERU-111 + Enzalutamide, Abiraterone	Metastatic Castration-resistant Prostate Cancer	Phase 3
Enobosarm & Abemaciclib Combo + non-steroidal AI, or steroid...	Metastatic Breast Cancer	Phase 3
Enobosarm + Exemestane	Metastatic Breast Cancer	Phase 3
VERU-111	SARS-CoV Infection	Phase 3
Enobosarm + Semaglutide (Wegovy) weekly injection	Obesity & Overweight	Phase 2

Opportunities

Veru's primary growth opportunity lies in addressing the massive, unmet need for muscle preservation within the booming GLP-1 weight loss drug market, potentially creating a new standard-of-care combination therapy.

A secondary opportunity exists in targeting residual inflammatory risk in atherosclerosis, a large patient population inadequately served by current lipid-lowering drugs.

Risk Factors

Key risks include clinical failure of its lead candidates in later-stage trials, significant dilution or inability to raise necessary capital as a pre-revenue company, and intense competition from larger pharmaceutical firms with greater resources in both the obesity and cardiovascular spaces.

Competitive Landscape

Enobosarm faces emerging competition in the muscle-preservation niche for GLP-1 therapy but may have a first-mover data advantage. Sabizabulin enters a more established anti-inflammatory atherosclerosis market against approved drugs like colchicine, requiring clear differentiation in efficacy or safety to gain traction.